(304 days)
Silverlon™ Wound Packing Strips are sterile, non-adherent, silver wound dressings. The Prescription Professional indications: Control of local wound bleeding and nasal hemorrhage, to encourage draining by wicking fluids from a body cavity, infected area, or abscess, and to help remove necrotic tissue from ulcers or other infected wounds when used as a "wet-to-dry" packing.
Silverlon® Wound Packing Strips are made of flexible, sterile, r non-adherent fabric of a knitted continuous nylon fiber substrate with a metallic silver surface containing approximately 1% silver oxide. Silverlon® Wound Packing Strips are designed to intimately contact the wound as a primary dressing and permit the passage of fluids. The silver provides effective protection of the dressing against microbial contamination. The nylon fabric permits the passage of oxygen and fluids to and from the wound. The surface of the nylon fibers in Silverlon® Wound Packing Strips consists of a thin layer of metallic silver containing approximately 1% silver oxide that provides effective protection of the dressing against microbial contamination.
The provided text focuses on the 510(k) premarket notification for Silverlon™ Wound Packing Strips, determining its substantial equivalence to predicate devices, and outlining its intended use and functional characteristics. However, it does not contain information related to acceptance criteria or a study proving device performance against such criteria in the manner typically seen for complex medical devices requiring such studies (e.g., AI algorithms, diagnostic tests).
Instead, the document details:
- Device Description: What the Silverlon™ Wound Packing Strips are made of (silver-nylon), how they function (intimate wound contact, fluid passage, antimicrobial protection), and their physical properties.
- Intended Use/Indications for Use: Control of local wound bleeding/nasal hemorrhage, encouraging fluid drainage, and helping remove necrotic tissue, especially in "wet-to-dry" packing.
- Predicate Devices: Argentum Research's Silverlon™ Contact Wound Dressing (K981299) and Johnson and Johnson's Nu Gauze Packing Strips.
- Substantial Equivalence Claim: The technological characteristics are substantially equivalent to predicate devices.
- Performance Data Assessment (Biocompatibility): The fabric was subjected to standard in vitro and in vivo biocompatibility tests (cytotoxicity, sensitization, acute intracutaneous reactivity, acute systemic toxicity, and tissue compatibility via muscle implantation study) according to ISO 10993. These studies, performed by North American Science Associates, Inc. (NAMSA), indicated safety for intended use.
Therefore, I cannot populate the requested table or answer most of the questions because the document does not provide acceptance criteria, performance metrics (like sensitivity, specificity), ground truth establishment, sample sizes for test/training sets, or details of efficacy studies in the context of clinical performance or AI/software.
The provided text describes a submission for a wound dressing, and the "performance data" mentioned refers to biocompatibility testing, not clinical efficacy metrics or performance criteria as might be expected for a diagnostic or AI-driven device.
Based on the provided text, the requested information cannot be fully extracted as it is not present. The document focuses on regulatory approval (510(k)) via substantial equivalence and biocompatibility, not a clinical trial proving a specific performance metric against acceptance criteria.
Summary of what can be inferred from the text:
- Acceptance Criteria & Reported Device Performance: Not explicitly stated in terms of quantitative clinical performance metrics (e.g., sensitivity, specificity, accuracy). The implicit "acceptance criterion" for the 510(k) process is "substantial equivalence" to predicate devices and acceptable biocompatibility.
- Biocompatibility Study: The study mentioned is a series of in vitro and in vivo biocompatibility tests (cytotoxicity, sensitization, acute intracutaneous reactivity, acute systemic toxicity, tissue compatibility via muscle implantation).
- Sample Size for Test Set: Not specified for biocompatibility studies beyond mentioning "tests."
- Data Provenance: Studies performed by North American Science Associates, Inc. (NAmSA), Northwood, Ohio. These are laboratory/animal studies, not human clinical trials.
- Number of Experts/Qualifications: Not specified; typically, such tests are conducted by trained laboratory personnel following standard protocols.
- Adjudication Method: Not applicable for standard biocompatibility testing.
- MRMC Comparative Effectiveness Study: Not applicable; this is for assessing human reader performance.
- Standalone Performance: The biocompatibility tests are for the material itself.
- Type of Ground Truth: For biocompatibility, the ground truth is established by the standard protocols of ISO 10993 (e.g., absence of cytotoxicity, sensitization, etc.).
- Sample Size for Training Set & Ground Truth for Training Set: Not applicable for this type of submission. The device is a physical dressing, not an AI/software.
{0}------------------------------------------------
SEP 2 4 1999
10.1 Summary Information
10.1.1 Submitter's Name and Address
Argentum Research Post Office Box 429 Lakemont, GA 30552
Contact person and telephone number:
A. Bart Flick, M.D., Research Director Telephone: (706) 782-6700 Telefax: (706) 782-3903
Date summary was prepared:
24 November 1998
10.1.2 Name of Device
| Trade Name: | Silverlon™ Wound Packing Strips |
|---|---|
| Common Name: | Silver-nylon wound packing strips |
| Classification Name: | Wound and Burn dressing |
10.1.3 Identification of predicate device to which substantial equivalence is being claimed
Silverlon™ Wound Packing Strips are substantially equivalent in function and intended use to: Argentum Research's Silverlon™ Contact Wound Dressing (K981299) and Johnson and Johnson's Nu Gauze Packing Strips (pre-amendment device).
10.1.4 Device Description
{1}------------------------------------------------
Explanation of how the device functions: Silverlon® Wound Packing Strips are designed to intimately contact the wound as a primary dressing and permit the passage of fluids. The silver provides effective protection of the dressing against microbial contamination.
Basic scientific concepts that form the basis for the device: The nylon fabric permits the passage of oxygen and fluids to and from the wound. The surface of the nylon fibers in Silverlon® Wound Packing Strips consists of a thin layer of metallic silver containing approximately 1% silver oxide that provides effective protection of the dressing against microbial contamination.
Significant physical and performance characteristics of the device such as device design, materials used, and physical properties: Silverlon® Wound Packing Strips are made of flexible, sterile, r non-adherent fabric of a knitted continuous nylon fiber substrate with a metallic silver surface containing approximately 1% silver oxide.
10.1.5 Statement of the intended use of the device, including general description of the conditions the device will mitigate and the patient population for which the device is intended
Silverlon™ Wound Packing Strips are sterile, non-adherent, absorbent wound dressings are designed as an interface between the wound and a conventional occlusive dressing. Indications are for control of local wound bleeding and nasal hemorrhage, to encourage draining by wicking fluids from a body cavity, infected area, or abscess, and to help remove necrotic tissue from ulcers or other infected wounds when used as a "wet-todry" packing. Topical application of Silverlon® Wound Packing Strips protects the wound area and the open weave of Silverlon® Wound Packing Strips permits passage of wound fluid through the product to be absorbed by an overlying absorbent material. The silver coating provides effective protection of the dressing against microbial contamination.
10.1.6 Statement of how the technological characteristics of the device compare to those of the predicate device
{2}------------------------------------------------
The technological characteristics of the device such as flexible primary contact wound dressing, permeability to oxygen and fluids, and protection against microbial contamination of the dressing are substantially equivalent to the predicate devices cited.
Assessment of Performance Data 10.2
The fabric that constitutes the Silverlon™ Wound Packing Strips subjected to standard in vitro and in vivo biocompatibility tests including cytotoxicity, sensitization, acute intracutaneous reactivity, acute systemic toxicity), and tissue compatibility (muscle implantation study . All tests were performed in accordance with Part-10993 of the International Standard Organization (ISO) Standard (Biological Evaluation of Medical Devices) by North American Science Associates, Inc. (NAmSA), Northwood, Ohio. The studies indicated that Silverlon® Packing Strips are safe for their intended use.
{3}------------------------------------------------
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three curved lines.
Public Health Service
SEP 2 4 1999
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
A. Bart Flick, M.D. Chief Executive Officer and Research Director Argentum International LLC P.O. Box 429 Lakemont, Georgia 30552
Re: K984210
Trade Name: Silverlon™ Wound Packing Strips Regulatory Class: Unclassified Product Code: FRO Dated: July 14, 1999 Received: July 26, 1999
Dear Dr. Flick:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{4}------------------------------------------------
Page 2 - A. Bart Flick, M.D.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Celia M. Witten, Ph.D., M.D.
Celia M. Witten, Ph.D., M.D. Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
INDICATIONS FOR USE 2.
510(k) Number (if known):
Device Name:
Silverlon™ Wound Packing Strips
Indications for Use:
Silverlon™ Wound Packing Strips are sterile, non-adherent, silver wound dressings. The Prescription Professional indications:
Control of local wound bleeding and nasal hemorrhage, to encourage draining by wicking fluids from a body cavity, infected area, or abscess, and to help remove necrotic tissue from ulcers or other infected wounds when used as a "wet-to-dry" packing.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use A (Per 21 CFR 801.109) (Optional Format 1-2-96)
OR
Over-The-Counter Use_
coillo
N/A